Objective: Cardiopulmonary bypass-mediated release of proinflammatory cytokines promotes the transendothelial migration of leukocytes. Among others, intercellular adhesion molecule (ICAM) is essential for this migratory process within the venous bypass graft, which finally contributes to a diminished early patency rate by thickening of the intima. Small interfering ribonucleic acids (siRNAs) are efficient and specific modulators of endogenous gene expression. This study describes the application of siRNAs to suppress ICAM-1 expression on the surface of human venous endothelial cells. Methods: Primary cultures of human venous endothelial cells were either transfected with ICAM-1 siRNA, with a scrambled control siRNA or cultured without transfection. ICAM-1 expression was analyzed with or without TNF-a stimulation by flow cytometry. Results: Upon TNF-a stimulation, cells transfected with ICAM-1 siRNA showed a six-to seven-fold decreased ICAM-1 expression compared to untransfected cells or cells transfected with the scrambled control siRNA. Conclusions: This is the first report that ICAM-1 expression can be effectively silenced by siRNAs on endothelial cells from human saphenous veins. This new technology may render novel therapeutic concepts to reduce early graft failure by protecting venous bypass grafts against early intra-or postoperative leukocyte infiltration. #
Introduction
Autologous saphenous vein grafts for coronary artery bypass grafting (CABG) continue to be indispensable in coronary surgery. The postoperative success of coronary revascularization strongly depends on the patency of the venous bypass grafts employed. In comparison with the use of arterial grafts, venous conduits show a lower patency rate. Up to 20% of the venous grafts fail within the first month after implantation [1] , 50% supposedly are occluded 10 years after implantation [2] . This leads to a de novo risk of myocardial damage and reduced quality of life in symptomatic patients. Therefore, strong interest exists to gain knowledge of the pathophysiological pathway resulting in early graft failure.
Several hypotheses exist accounting for the failure of bypass material. First, reduced bypass flow or limited diameter of the native vessel often causes an early occlusion. Second, technical factors as narrowed anastomosis are involved. However, a more significant alteration can be observed in the venous graft after implantation, namely a neointimal thickening comparable to early lesions seen in atherosclerotic altered vessels [3, 4] . Particularly, the intima thickening may be the cause of an early failure of the venous graft. Alternatively, it may be the basis for later development of graft atheroma. Recent investigations demonstrated a close relationship between the endothelial dysfunction and various different stimuli caused by surgery employing cardiopulmonary bypass, all leading to an activation of the endothelium. In consequence, the activated endothelium layer expresses different receptors on the cell surface, enabling leukocytes adherence and penetration through the endothelium. Consecutive reactions like the release of oxygen free radicals and cytotoxic mediators are leading to a stimulation of vascular small muscle cells, and finally, to hyperplasia and migration to the intima layer [5] .
Presuming the above-mentioned different factors, the expression of endothelial adhesion molecules can be accentuated as one of the central mediators leading to an intima thickening. They represent a group of different glycoproteins and carbohydrates expressed on the surface of a wide variety of cell types. Within the pathomechanism of intima thickening the intercellular adhesion molecule 1 (ICAM-1) seems to play a central role. ICAM-1, also known as CD54, is expressed on different cell types such as leukocytes, For a practical use the sequence of the targeted gene has to be identified in a gene library. Homologous to the genesequence double stranded siRNA is manufactured by commercial providers. SiRNAs may be either directly applied by cell transfection techniques or intracellularly transcribed as small hairpin RNAs from genes inserted by, for instance, lentiviral transduction into the cell genome. In the cytoplasm, one strand of the siRNA becomes part of a ribonucleoprotein complex called RNA-induced silencing complex (RISC). RISC can cleave RNA sequences complementary to the siRNA strand, thereby causing the rapid degradation of the target mRNA. Importantly, and in contrast to longer double-stranded RNAs, siRNAs are in most cases inefficient inducers of an interferon response leading to a general cytotoxicity [6] . However, some siRNAs have been shown to not only inhibit the expression of unintended targets, but also to induce a limited interferon response of the transfected cell in spite of their small size.
Recently, siRNAs have been used to diminish E-selectin expression in human umbilical vein endothelial cells (ECs) resulting in a reduced leukocyte adhesion [7] .
The aim of the present study was to evaluate the potency of siRNAs to transiently block ICAM-1 receptor expression in cultured primary venous endothelial cells from human vena saphena magna specimens.
Materials and techniques

Patients and isolation of the cells
The vein specimens were obtained from patients undergoing elective CABG. Written consent was obtained in each case and the study was agreed to by the Ethical Committee of Tuebingen University Faculty of Medicine. Upon the decision we had to collect the specimens anonymously. Thus, we have no information on the medications of the patients prior to surgery. Exclusion criteria were an ongoing infection, usage of other venous material but the saphenous vein and a time delay between harvesting and further preparation of more than 3 h.
Isolation and cultivation of endothelial cells from saphenous vein specimens: harvesting and culture of cells were in accordance with other publications [8, 9] .
All culture plates and flasks were coated overnight with collagen (40%) (Collagen G, Biochrom, IN, USA). After incubation of the vein in RPMI 1640 (containing 0.5%/ml gentamycin) it was rinsed with a buffer solution (137 mM NaCl/5.4 mM KCl/4.2 mM NaHCO 3 /5 mM D-glucose in 500 ml H 2 O, pH 7.3, sterile). Endothelial cells were harvested by collagenase (0.1% in PBS, PAA Laboratories GmbH, Cölbe, Germany) and further cultured in EGM-2 (+bullet kit, Cambrex Bio Science Verviers, S.p.r.l., Verviers, Belgium). The cells were splitted after reaching confluence. For all experiments cells from the third passage were used. Purity of the human venous endothelial cells (HVECs) was controlled by staining with a FITC-labeled antibody for human VEGFR-2 and CD 31 (Becton Dickinson GmbH, Heidelberg, Germany).
siRNA transfections of HVECS
The ICAM-1 siRNA sequences were 5 0 -GCCUCAGCACGUACCUCUAdTdT-3 0 (sense) and 5 0 -UAGAGGUACGUGCUGAGGCdTdT-3 0 (antisense) [10] ; the scrambled siRNA sequences were 5 0 -UUCUCCGAACGUGUCACGUdTdT-3 0 (sense) and 5 0 -ACGUGACACGUUCGAGAAdTdT-3 0 (antisense). SiRNAs were purchased from CureVac (Tuebingen, Germany) or from Qiagen (Hilden, Germany).
For siRNA transfections, HVECs were cultured in collagencoated 12-well plates without antibiotics. After reaching 70-80% confluence, HVECs were transfected with 100 nM of siRNA using 2.0 mg/ml Cellfectin (Invitrogen GmbH, Karlsruhe, Germany) for 2 h in serum-free medium followed by the replacement of the supernatants with EGM-1. Nine hours later, HVECs were stimulated with 2.5 ng/ml TNF-a (Immunotools, Friesoythe, Germany) for 15 h followed by FACS analysis.
FACS-analysis
After washing HVECs with EGM-2 media, unspecific binding of antibodies was blocked by incubation in 0.5% FCS. A PElabeled antibody against human ICAM-1 (Becton Dickinson GmbH) was used to stain the HVECs (4 8C, 1 h). After washing and detaching, the cells were fixed with 2.5% paraformaldehyde in PBS. Flowcytometric analyses (5000 cells/measurement) were performed in a FACScan TM (Becton Dickinson GmbH) and evaluated with the CellQuestPro software (Becton Dickinson GmbH). The results shown represent the averages of three independent experiments. All experiments were performed with cells obtained from the same primary cell culture.
Statistical procedure
The results were expressed as mean (M) AE standard deviation (SD). Statistical analysis was performed by the statistics software package SPSS (SPSS Software Inc., Chicago, USA). Statistical significance of differences between the groups was examined by ANOVA.
Results
Titration of HVECs with increasing TNF-a concentrations showed a dose-dependent induction of ICAM-1 expression (Fig. 1 ). Upon treatment with 78 pg/ml TNF-a the percentage of ICAM-1 positive cells raised from less than 2% to 50%, and treatment with 2.5 ng/ml caused a raise to 80%. A further increase of the TNF-a concentrations resulted only in a minor increase of ICAM-1 expression as judged by flow cytometry analysis. Therefore, we chose a TNF-a concentration of 2.5 ng/ml for ICAM-1 induction for further experiments.
Next, we analyzed the efficacy and specificity of siRNAs to negatively interfere with TNF-a induced ICAM-1 expression in HVECS. For that, prior to TNF-a stimulation, we transfected HVECs either with ICAM-1 siRNA or with a scrambled siRNA serving as sequence-unrelated control.
In this set of experiments, TNF-a stimulation of nontransfected HVECs induced ICAM-1 expression in 93 AE 1.2% of cells compared to only 1.7 AE 0.60% positive cells without TNF-a stimulation (Fig. 2) . Transfection with the scrambled siRNA hardly affected the extent of ICAM-1 expression (79 AE 3.9%). However, transfection with ICAM-1 siRNA decreased the percentage of stimulated ICAM-1 positive cells to 13 AE 2.7% ( p < 0.0001 compared to nontransfected cells and to scrambled siRNA transfected cells). The decrease in ICAM-1 positive cells was paralleled by a reduction of relative expression levels of ICAM-1 upon ICAM-1 siRNA treatment (Fig. 3) . Whereas TNF-a stimulation caused a 13-fold increase of ICAM-1 expression in untransfected cells, and an eight-fold increase in cells transfected with control siRNA, ICAM-1 siRNA treated cells showed only a twofold increase in ICAM-1 expression ( p < 0.01) compared to unstimulated cells.
Comment
Failure of venous bypass material is a well-known problem in coronary and peripheral vascular surgery. It potentially causes life-threatening events. In addition to technical problems, dysfunction of the endothelium with expression of adhesion molecule leads to an intima thickening of the graft. This additional occlusion probably contributes to bypass failure. In the past years, several factors could be determined leading to adhesion molecule expression on endothelial cells. In cardiac surgery, the use of extracorporeal circulation induces the release of different inflammatory cytokines, some of them are known as strong stimuli for adhesion molecule expression. Furthermore, the mechanical trauma while harvesting the venous conduits multiplied by pressure distension of the graft for inspection or overcoming spasm may act as a further important stimulus [11] . Modified flow pattern in the graft with increased tangential wall stress and shear stress on the endothelium acts as a further mechanical trauma inducing adhesion molecule expression. So it can be outlined that a potpourri of different stimuli causes the same result namely an expression of adhesion molecules on the endothelial cells of venous bypass material leading to a neointima thickening. In our setting, we used TNF-a to induce adhesion molecule expression; definitely, it can be provoked by others as well.
One of the central adhesion molecules that is responsible for transendothelial leukocyte migration is ICAM-1. Zou and coworkers [12] observed a 30-50% reduction of neointimal hyperplasia in ICAM-1 deficient mice in comparison to wild types. These results support the hypothesis that silencing of ICAM-1 expression in venous bypass material may represent a promising approach to reduce the intima thickening that may represent a first step in an occlusion of the venous coronary bypass.
The recent discovery of RNA interference by Tuschl and coworkers [13] opens new techniques with high potential for non-viral and transient gene therapeutic therapies.
This study describes the inhibition of ICAM-1 expression by application of specific siRNA. Cultures of endothelial cells from human saphenous veins were stimulated with TNF-a.
In the present study, FACS-analyses showed an ICAM-1 expression after TNF-a stimulation of 93% compared to 1.7% in unstimulated HVECs. After a non-viral transfection with ICAM-1-specific siRNA, the stimulated expression of ICAM-1 on the cell surface could be diminished to 13%. These results are encouraging for further investigations analyzing the power of siRNA to reduce the danger of bypass failure.
The minor reduction of ICAM-1 expression seen upon transfection with scrambled siRNA indicates a slight toxic effect generally observed for cationic lipid mediated transfections. The results clearly demonstrate the high potency of designed siRNAs to suppress the expression of the ICAM-1 adhesion molecule in HVECs.
Especially, CABG surgery represents an ideal application for siRNA use. In general, there is a time delay between harvesting and implantation of the venous graft so that the material can be easily manipulated with siRNAs during this period. In addition, the graft can be treated ex vivo so that neither local cross clamping techniques nor systemic application of siRNA is necessary. Thus, a systemic delivery of siRNAs may not be necessary in such a therapeutic setting. First results obtained after ex vivo transfection of venous bypass material with nucleic acids are very encouraging [14, 15] .
This study demonstrates that siRNA can be transfected by a non-viral carrier in human venous endothelial cells and that it can successfully knockdown ICAM-1 expression. Further animal experiments have to confirm whether the effect of a reduced ICAM-1 expression in venous bypass material also results in a diminished rate of intima thickening and therefore in a reduced rate of an early failure of the bypass material in coronary artery bypass grafting, too. Nevertheless, blocking ICAM-1 function does not completely prevent leukocyte migration. Additional adhesion molecules such as vascular cell adhesion molecule (VCAM), plateletendothelium cell adhesion molecule (PECAM), endotheliumselectin (E-selectin) or platelet-selectin (P-selectin) are likely to be involved in leukocyte adhesion to the endothelium. We are currently developing siRNAs to suppress each of these surface markers on HVECs.
In the long run, this new technology may offer novel therapeutic concepts to reduce early graft failure in coronary and peripheral vascular surgery by protecting recently implanted venous bypass grafts against leukocyte infiltration and intima thickening. figure. (B) Graphic presentation of relative ICAM-1 expression. Relative expression levels were calculated using the geometric means and normalized to untreated and uninduced cells. Cells were treated as described in Fig. 2 . The transfected siRNAs and the TNFa treatment are indicated in the figure.
